ISSN 2147-9720 | E-ISSN 2148-4279
Case Report
Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF
1 Division of Rheumatology, Department of Internal Medicine, Health Sciences University Gülhane School of Medicine, Ankara, Turkey  
Eur J Rheumatol ; : -
DOI: 10.5152/eurjrheum.2018.17183
Key Words: Tocilizumab, AA amyloidosis, familial mediterranean fever
Abstract

There is no established treatment protocol for amyloid-A (AA) amyloidosis secondary to Familial Mediterranean Fever (FMF). Recently, we reported the efficacy of tocilizumab in 11 amyloidosis cases associated with FMF. In 2 patients of 11, we discontinued the tocilizumab administeration owing to the normalization of amyloidosis-related symptoms, but proteinuria re-occurred eventually. Fortunately, the patients responded to tocilizumab re-treatment. This led us to conclude that physicians should not stop the treatment, even in patients with normalized proteinuria levels.


Cite this article as: Yılmaz S, Tekgöz E, Çınar M. Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF. Eur J Rheumatol DOI: 10.5152/eurjrheum.2018.17183.

Key Words
Authors
All
Author’s Corner
Survey
AVES | Copyright © 2018 Medical Research and Education Association | Latest Update: 27.08.2018